GemOx

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma. When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: # Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; # Gemcitabine - an antimetabolite; # Oxaliplatin - a platinum-based alkylating antineoplastic agent.

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma. When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R. The [R]-GemOx regimen consists of: Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells; Gemcitabine - an antimetabolite; Oxaliplatin - a platinum-based alkylating antineoplastic agent.

Dosing regimen

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1294953028 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001294953028 · captured 1749579309.0 · version history

Cite this page as: encyclopegia.org, “GemOx”, snapshot enwiki-001294953028. https://encyclopegia.org/a/gemox

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.